| Dr. Gary L. Olson, CEO/CSO |
|
Dr. Olson is co-founder, President & CEO of Provid Pharmaceuticals. He received an A.B.
from Columbia and his Ph.D. in chemistry from Stanford. He is a leading expert in medicinal
chemistry and a pioneer in the fields of drug design and peptide mimetics.
Dr. Olson was a research scientist at Hoffmann-La Roche for 26 years where he became Research
Director in the Departments of Inflammation/Autoimmune disease and Oncology. In 1998, he joined
Praecis Pharmaceuticals as Senior Vice President of Chemistry R&D. He co-founded Provid in 2001
and has led the company's drug discovery services business and internal programs in
autoimmune disease and oncology therapeutics. He is also an adjunct Professor of Medicinal
Chemistry at Rutgers.
|
| Mr. Edwin Thomas, COO/CFO |
|
Mr. Thomas is a biotechnology executive and entrepreneur, having been a founder, advisor,
and principal in a number of successful life science companies. Prior to joining Provid, Mr.
Thomas occupied executive positions with CMI - Centers for Medical Innovation AG (antivirals,
Munich and Princeton), Precision Pharmaceuticals Inc. (anti-inflammatories, Gainesville FL),
and Avid Therapeutics (antiviral drug discovery, Philadelphia). Mr. Thomas was educated at
the University of Pennsylvania (B.S., Economics and Biochemistry, 1981) and earned an MBA
from The Wharton School in 1984.
|
| Dr. Christopher Self, VP Medicinal Chemistry |
|
Dr. Self has broad experience in the pharmaceutical
industry and expertise in organic and medicinal chemistry applied in
the fields of inflammation, autoimmune diseases, and oncology. He
received a B.Sc. in chemistry from Imperial College, London in 1977, and his
Ph.D. at the University of London under the direction of Prof. Stephen
Ley. Following a postdoctoral appointment at Wisconsin with Prof. Barry
Trost, he joined Roche Products Ltd., UK, in 1982 as a senior researcher in
the Department of Inflammation, and from 1995 held the position of Research
Leader at Hoffmann-La Roche Inc., USA in the Department of
Inflammation/Autoimmune Diseases. In 1998, Dr. Self became Vice President, Medicinal
Chemistry of Praecis' New Jersey division, and became a co-founder of Provid in 2001
where he is currently Vice President of Medicinal Chemistry.
|
| Dr. Charles M. Cook, VP Information Sciences |
|
Dr. Cook is a leading computational chemist in the field of industrial molecular modeling.
He received an A.B. in chemistry and computer science from Cornell University in 1976,
and his Ph.D. in chemistry from Princeton University where he worked with Prof. Leland Allen.
He joined Hoffmann-La Roche in 1983 in the Department of Physical Chemistry in the
molecular modeling group. His expertise in molecular modeling and computational methods includes
ab initio and semiempirical quantum approaches, molecular mechanics and dynamics, protein homology
modeling, docking methodology, pharmacophore determination, conformational analysis, force field
development, and structural database technology.
Dr. Cook joined Praecis' New Jersey division in 1998 as Vice President, Computational Sciences,
and co-founded Provid in 2001 where he serves as Vice President, Information Sciences.
|
|
